Scinai Immunotherapeutics Ltd. announced the execution of a formal amendment to its finance contract with the European Investment Bank (EIB). The amendment extends the maturity date of the contract by four years from December 31, 2027, to December 31, 2031.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.44 USD | -3.30% | +0.09% | -26.10% |
1st Jan change | Capi. | |
---|---|---|
-26.10% | 1.98M | |
+29.03% | 48.16B | |
-0.10% | 41.73B | |
+43.45% | 41.03B | |
-5.26% | 28.77B | |
+11.48% | 25.59B | |
-22.74% | 18.96B | |
+9.06% | 12.92B | |
+30.01% | 12.03B | |
-1.51% | 11.77B |
- Stock Market
- Equities
- SCNI Stock
- News Scinai Immunotherapeutics Ltd.
- Scinai Immunotherapeutics Ltd. Extends Maturity of Its Finance Facility with Scinai Immunotherapeutics from 2027 to 2031